Arcus Biosciences President Executes $2M Stock Sale Amid Strong Annual Returns

Arcus Biosciences’ President, Juan C. Jaen, sold approximately $2.1 million worth of company stock on December 4, 2025, according to a recent SEC Form 4 filing. The transaction involved the indirect sale of 82,997 shares through a trust at a weighted average price of about $24.71 per share, representing roughly 5.91 % of his total holdings. Post‑sale, Jaen still holds 367,220 shares directly and 954,063 shares indirectly via the trust. The sale occurred as Arcus’ stock delivered a nearly 48 % one‑year total return, with shares trading near annual highs at the time. All shares were sold indirectly rather than from Jaen’s direct holdings, and this transaction was larger than his recent median insider sale. Arcus Biosciences is a clinical‑stage biotechnology company focused on developing immuno‑oncology therapies. Its stock has been volatile, influenced by clinical trial updates and biotech market dynamics, but retains investor interest due to its pipeline in cancer treatments. #ArcusBiosciences #InsiderTrading #BiotechStocks #StockMarketNews #SlimScan #GrowthStocks #CANSLIM